Compare Virgin Galactic Holdings, Inc. (SPCE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Virgin Galactic Holdings, Inc. trades at $3.28 (market cap $498.02M), while State Street SPDR S&P Biotech ETF trades at $159.91. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| SPCE | XBI | |
|---|---|---|
Market Cap | $498.02M | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $7.52 | $164.28 |
52-Week Low | $2.17 | $86.92 |
Enterprise Value | $597.87M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.23, up 4.19% on the day, with a bullish technical signal from moving averages but overbought RSI levels near 91.63. The company continues to report significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations of $240.14 million. Recent news highlights focus on upcoming Q2 2026 earnings and sector volatility amid SpaceX's market debut.
The outlook remains high-risk due to persistent unprofitability and cash burn, though recent quarterly EPS beats offer some optimism. Investment opportunity hinges on successful commercialization of space tourism, while risks include intense competition, funding needs, and execution challenges. Analyst sentiment is mixed with 29.41% buy ratings.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
